Sign up Australia
Proactive Investors - Run By Investors For Investors

ImpediMed enrols first patient in chronic heart failure trial

The company is planning its European launch in calendar year 2017
Heart failure currently costs the U.S. circa US$31bn per year

ImpediMed Ltd (ASX:IPD) has enrolled the first patient in its initial chronic heart failure (CHF) trial using the company’s “SOZO” device.

SOZO uses bioimpedance spectroscopy (BIS) technology to manage and monitor a person’s fluid status, body composition and hydration in a clinical or at-home setting.

This initial study will monitor up to 30 patients with chronic heart failure in a clinical setting for 30 days, and is expected to be completed in the calendar year 2017.

READ: ImpediMed begins lymphoedema study using its health device

If successful, SOZO is expected to provide an early warning system for cardiac decompensation with the potential to optimise patient care and significantly reduce hospital readmissions.

The real-world data generated will be used to form the basis for the design of a larger scale trial expected to be initiated by late 2017.

CHF is among the most expensive diseases in the U.S with an estimated 6.5 mln people suffering from heart failure, with more than 850,000 new patients diagnosed each year.

Heart failure currently costs the U.S. circa US$31bn per year, and is estimated to increase to US$70bn by 2030.

The company obtained CE (European Conformity) mark for SOZO in June 2017 and plans to initiate the European launch of SOZO in key commercial sites in calendar year 2017.

View full IPD profile View Profile

ImpediMed Timeline

November 14 2013

Related Articles

picture of cannabis plants
March 24 2018
Control of the supply chain offers operational advantages and financial benefits.
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use